Thus, in vivo CXCL12 inhibition with NOX-A12 led to a tumor microenvironment less receptive for MM cells, causing reduced MM cell growth and disease progression (115) (Figure 1). This evidence concerns the gene CXCL12 and Miyoshi myopathy.